## **Core Concept**
The combined test of first-trimester screening for pregnancy involves assessing various biochemical and biophysical markers to evaluate the risk of chromosomal abnormalities, such as Down syndrome. This test typically includes a combination of ultrasound measurements and maternal serum biochemical analytes.

## **Why the Correct Answer is Right**
The correct answer, , includes **free beta-human chorionic gonadotropin (β-hCG)**, **pregnancy-associated plasma protein-A (PAPP-A)**, and **ultrasound markers like nuchal translucency (NT) thickness**. These markers are significant because:
- **Free β-hCG** levels are often elevated in pregnancies complicated by Down syndrome.
- **PAPP-A** levels are typically decreased in Down syndrome pregnancies.
- **Nuchal translucency (NT)** thickness is an ultrasound marker that, when increased, is associated with a higher risk of Down syndrome and other chromosomal abnormalities.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option lacks specificity regarding the components of the combined test, making it less accurate.
- **Option B:** While **β-hCG** and **PAPP-A** are indeed part of the biochemical screening, this option misses the critical inclusion of **NT** and possibly other markers.
- **Option D:** This option seems to introduce **inhibin-A** and **estriol**, which are more commonly associated with the second-trimester screening (quad screen) rather than the first-trimester combined test.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the combined first-trimester screening test provides a more accurate risk assessment when both biochemical markers (**free β-hCG** and **PAPP-A**) and the **nuchal translucency (NT) thickness** are considered together. This integrated approach helps in early identification of high-risk pregnancies.

## **Correct Answer:** .